LUMA Vision's Groundbreaking Cardiac Advancements with VERAFEYE™
Dublin - LUMA Vision Ltd., a pioneer in cardiac 4D navigation technology, has made significant strides in the medical field by successfully completing 15 VERAFEYE™-guided persistent atrial fibrillation (AF) ablation procedures. This achievement showcases the potential to enhance patient care in complex cardiac procedures.
The Role of VERAFEYE in Cardiac Ablation Procedures
This study is crucial for assessing VERAFEYE's capabilities in guiding catheter ablation therapy. This includes various processes such as pulmonary vein isolation, posterior wall isolation, and cavotricuspid isthmus ablation, all efficiently facilitated by the use of the CardioFocus QuickShot™ Nav pulsed field ablation (PFA) catheter system.
Integration of Advanced Imaging and Navigation
Results from the procedures revealed VERAFEYE's effectiveness in merging high-resolution intracardiac imaging with advanced navigation techniques. The integrated approach generates digital anatomical representations, enabling clinicians a comprehensive four-dimensional view of the beating heart.
This innovative method simplifies the ablation workflow, allowing procedures to be completed with just two catheters while boosting precision and operational efficiency.
Expert Insights on the Procedure
Dr. Ante Anic, Director of Electrophysiology at KBC Split in Croatia, acknowledged the unique features of the VERAFEYE system. He stated, "Using an empirical lesion set is the preferred approach for de novo AF ablation in the persistent population. With the VERAFEYE’s innovative 3D geometry creation, I utilized only one catheter for all imaging and navigation tasks, which positions us favorably in the market for procedural efficiency.”
Future Implications for Cardiac Care
Fionn Lahart, CEO of LUMA Vision, expressed gratitude towards their partners for supporting this ground-breaking initiative. He commented, “The success of these procedures is a pivotal achievement for LUMA Vision as we strive for enhanced accuracy and efficiency in cardiac treatments. VERAFEYE represents a paradigm shift in cardiac guidance technology driven by advanced AI and machine learning.”
Potential Future Applications
As confidence in this technology grows, there are plans to explore additional capabilities of VERAFEYE, such as guiding left atrial appendage closure and other structural heart procedures. The clinical implications are significant, promising to improve effects on cardiac interventions.
About LUMA Vision
LUMA Vision, based in Dublin, Ireland, with operational roots in Munich, Germany, specializes in innovative medical technology. The company is dedicated to enhancing how clinicians visualize and perform cardiac ablations through their flagship platform, VERAFEYE™. This system provides a comprehensive intracardiac view, facilitating precision in electrophysiology and structural heart procedures.
Frequently Asked Questions
What is the significance of VERAFEYE™ in cardiac care?
VERAFEYE™ enhances cardiac care by providing high-resolution imaging and navigation, streamlining complex procedures like AF ablations.
Who participated in the clinical study involving VERAFEYE™?
The clinical study involved LUMA Vision and its partners, including CardioFocus, Inc.
What are the expected future applications of VERAFEYE™?
Future applications may include its use in left atrial appendage closures and other structural heart interventions.
How does VERAFEYE™ improve procedural efficiency?
It simplifies the ablation process by allowing procedures to be completed with fewer catheters while ensuring greater precision.
What is LUMA Vision's mission?
LUMA Vision aims to transform cardiac care through innovative technology that enhances treatment outcomes and patient safety.
